Compare Abeona Therapeutics Inc (ABEO) vs Dover Corp (DOV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Dover Corp — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Dover Corp trades at $210.47 (market cap $28.82B). The key difference: Dover Corp is far larger — about 77.2× Abeona Therapeutics Inc's market cap, and Dover Corp pays a 0.97% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DOV | |
|---|---|---|
Market Cap | $373.32M | $28.82B |
Sector | Health | Industrials |
52-Week High | $7.23 | $233.31 |
52-Week Low | $4.17 | $161.16 |
Enterprise Value | $228.22M | $30.47B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Dover Corporation (DOV) trades at $214.05, up 0.16% on the day, with a bearish technical signal but strong fundamentals including a 13.3% net income margin and consistent earnings beats. Recent news highlights AI data center demand tailwinds and product launches across its subsidiaries. The stock shows healthy profitability with ROE at 15.06% and a P/E of 26.84, while analyst consensus is bullish with a $251 price target.
Outlook remains positive driven by earnings momentum and AI-related growth, though technical weakness and market volatility pose near-term risks. The stock offers value with a 17% upside to consensus target, supported by dividend payments and institutional confidence, but investors should monitor execution on data center opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →
